截至2025年9月11日收盘，国际医学(000516)报收于5.14元，上涨0.39%，换手率0.99%，成交量21.91万 手，成交额1.12亿元。 董秘最新回复 投资者： 现在广东在实行门诊按人头打包付费模式，请问贵公司对此是否了解，如果全国开始统一实 行，贵公司会不会因为业绩亏损导致最终退市，其次在本次中报中可以看到贵公司前十大股东都是自己 人，为什么会被机构弃如敝履？最后贵公司大量裁员是否属实？ 董秘： 您好，感谢您对公司的关注。公司将深入研究国家政策，积极应对医保支付方式改革。经过多 年发展，公司经营规模不断扩大，医疗综合实力持续增强，公司也将根据社会、经济和自身发展需要， 发挥体制优势，灵活调整经营策略。目前，公司不存在因财务类指标触及退市的情形。 投资者： 请问贵公司中心医院是否全面建设完成？床位使用率如何？在自我能力受限时是否有计划引 入第三方配套项目提升床位使用率，其次质子医院开业在即，对于质子医院是否对接商业保险？有哪些 商业保险与贵公司展开合作？ 投资者： 请问贵公司在Ai辅助医疗方面有哪些布局，现在处于什么阶段？ 董秘： 您好，感谢您对公司的关注。公司对前沿技术始终保持高度关注，旗下医 ...

在北京成功举办首届论坛之后， 第二届医疗器械研发创新论坛 将于 2025年国际医疗器械设计与制造技术展览会（Medtec China2025） 期间在 上海世博 展览馆 举行。 本届论坛由思宇MedTech与Informa Markets旗下Medtec China团队联合策划，邀请企业创始人、研发负责人、科技成果转化专家等，共同 探讨产品创新的路径与落地机制。 会 议议程 （ 报 名 方 法 附 文 末 ） 日期：2025年9月25日星期四全天 上午： 09 :30-09:35 开幕 致辞 09:35-09:55 《研究型医院医工融合创新与转化工作探索》 雷娟 四川西部医药技术转移中心 理事长/主任 中国医学装备协会医疗器械创新与应用分会 副会长 09:55-10:15 《介入新技术以及相关专利》 曹刚毅 环心医疗 CEO 10:15-10:35 《打造多层次医疗科技集群：巴塞尔药谷的成功实践》 11:15-11:35 《Chro-Mg™时控降解镁合金的研发与转化》 时晨 英诺科 CEO 下午议程： 13:30-13:50 《医疗器械研发全流程及海外案例》 赵清 思宇MedTech 创始人 13:50-14 ...

Group 1 - The article highlights the global debut of the AI catheter shaping robot at the OCIN2025 conference, showcasing advancements in intelligent diagnosis and treatment for cerebrovascular diseases [3][6] - The AI catheter shaping robot, developed in collaboration with leading medical teams, has received China's first "AI + treatment" Class III medical device registration certificate [5] - The robot's live surgery demonstration allowed experts to observe its ability to automatically shape catheters and navigate complex vascular paths, emphasizing the innovation in cerebrovascular intervention surgery [6] Group 2 - Lingyi Biotech presented significant clinical progress on gene therapy drugs for Wilson's disease and Gaucher disease type I at the ASGCT2025 conference, indicating important scientific and clinical implications [8] - Huayi Lekan introduced a novel gene therapy candidate for phenylketonuria (PKU) at ASGCT2025, which utilizes an innovative mechanism to silence mutated PAH genes and restore normal function [11][12] - New gene editing therapy GEN6050X for Duchenne muscular dystrophy (DMD) showed promising biomarker data, suggesting its potential to enhance cardiac function and overall patient outcomes [14] Group 3 - Xibiman Biotech announced early clinical results for C-CAR168, a novel CAR-T therapy targeting refractory lupus nephritis, indicating significant progress in treating autoimmune diseases [15] - The NyokAssist® artificial heart device demonstrated encouraging preliminary results at the ISHLT2025 conference, showcasing its design and low complication rates [18] - Shizai Biotech received approval for clinical trials of a new drug for amyotrophic lateral sclerosis (ALS), marking a significant step in addressing one of the "five major incurable diseases" [20] Group 4 - The establishment of a key laboratory for recombinant protein synthesis in Beijing, co-founded by Yuanwei Technology and Tsinghua University, aims to tackle challenges in the industrial application of synthetic biology [22][24] - Haowei Medical completed the first patient enrollment for a clinical trial of absorbable embolization microspheres for symptomatic uterine fibroids, marking a milestone in interventional treatment in China [26] - Sequoia China has invested in over 200 high-growth medical health companies, with more than 45 successfully completing IPOs across various stock markets [27][28]

Core Viewpoint - The rapid advancement of artificial intelligence technology is leading to an increase in AI-assisted medical scenarios, particularly in ultrasound technology and robotic applications for efficient patient care [1][2]. Group 1: Technology Development - The research team from the Chinese Academy of Sciences has developed intelligent ultrasound technology and ultrasound robots to provide convenient and efficient medical services [1]. - The proposed "robot + AI + handheld ultrasound" technology aims to address the complexity of ultrasound operations, which heavily rely on the expertise of ultrasound doctors [1]. - The team has integrated AI image analysis, operator action analysis, and autonomous decision-making of robots to achieve multi-modal information fusion and decision-making [1]. Group 2: Product Features - The developed lightweight desktop robot for thyroid and carotid artery examinations allows for guided scanning paths and real-time quality monitoring, enabling operators to follow robot prompts for standardized scanning [1]. - An AI diagnostic engine has been created based on extensive ultrasound image data to enhance the sensitivity and specificity of lesion identification [2]. - The ultrasound probe and processing system have been miniaturized to the size of a mobile phone, combined with a cloud-based intelligent analysis system, facilitating a service model that brings equipment to communities while experts operate remotely [2]. Group 3: Implementation and Impact - The technology has been implemented in over 10 grassroots medical institutions, conducting nearly 100,000 carotid ultrasound screenings [3]. - The research team is expanding the technology to include screenings for additional organs such as the breast and liver, aiming to make high-quality medical resources more accessible [3].

Core Insights - The rapid iteration of artificial intelligence technology is increasing the scenarios for AI-assisted healthcare, with a focus on intelligent ultrasound technology and ultrasound robots developed by the Chinese Academy of Sciences' Automation Research Institute [1][2] - The developed technology aims to address the complexity of ultrasound equipment operation, which heavily relies on the expertise of ultrasound doctors, particularly in underdeveloped areas where misdiagnosis can delay treatment [1] - The research team has created a lightweight desktop robot for thyroid and carotid artery examinations, integrating AI image analysis and real-time monitoring to facilitate standardized scanning by operators [1] Group 1 - The intelligent ultrasound technology can be used for precise assessment of organ lesions, serving as an important tool for early screening of cardiovascular diseases and cancers [1] - The team has developed an AI diagnostic engine based on extensive ultrasound image data, enhancing the sensitivity and specificity of lesion identification [2] - The ultrasound probe and processing system have been integrated into a device the size of a mobile phone, enabling a service model that brings equipment to communities while experts analyze data in the cloud [2] Group 2 - The technology has been implemented in over 10 grassroots medical institutions, conducting nearly 100,000 carotid ultrasound screenings [3] - The research team is expanding the technology to include screenings for additional organs such as the breast and liver, aiming to make quality medical resources more accessible [3]